January 8, 2018 / 1:44 PM / 5 months ago

BRIEF-Immunomedics, Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totalling $250 Mln

* IMMUNOMEDICS AND ROYALTY PHARMA ANNOUNCE ROYALTY FUNDING AND STOCK PURCHASE AGREEMENTS TOTALLING $250 MILLION

* IMMUNOMEDICS INC - ROYALTY PHARMA ACQUIRES ROYALTY RIGHTS ON GLOBAL NET SALES OF SACITUZUMAB GOVITECAN (IMMU-132) ACROSS ALL INDICATIONS FOR $175 MILLION

* IMMUNOMEDICS INC - ROYALTY PHARMA HAS ALSO PURCHASED $75 MILLION IN COMMON STOCK OF IMMUNOMEDICS, AT $17.15 PER SHARE

* IMMUNOMEDICS - TRANSACTION WILL PROVIDE SUFFICIENT CASH TO FUND OPERATIONS INTO 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below